Turnstone Biologics is committed to bringing the next generation of viral immunotherapies to cancer patients. Learn about our science and pipeline.
Location: United States, New York
Total raised: $132.7M
Investors 6
| Date | Name | Website |
| - | PFM Health... | pfmhealths... |
| - | Brace Phar... | bracepharm... |
| - | OrbiMed | orbimed.co... |
| - | Teralys Ca... | teralyscap... |
| - | Fight Agai... | facit.ca |
| - | Eight Road... | eightroads... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 21.07.2021 | Series D | $80M | - |
| 02.11.2016 | Series B | $41.4M | - |
| 28.10.2015 | Series A | $11.3M | - |
Mentions in press and media 11
| Date | Title | Description |
| 21.07.2021 | Cancer Drugmaker Turnstone Biologics Raises $80 Million | Cancer-drug startup Turnstone Biologics Corp. has collected $80 million in new funding as venture-capital investment in oncology companies continues to climb. U.S. and European cancer drugmakers secured $6.9 billion in venture funding in th... |
| 21.07.2021 | Turnstone Biologics Raises $80 Million Series D Financing | Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, today announced the successful completion of an $80 million Series D financing co-led by PFM Health Sciences and Point72... |
| 02.11.2016 | Today in funding ($69.1M): Big Viking Games, Turnstone Biologics, Decisive Farming | Canadian companies are reporting are announcing major rounds today. Here’s the latest on who raised how much, and from whom. Big Viking Games raises $21.75 million Toronto-based Big Viking Games raised $21.75 million. According to a report ... |
| 02.11.2016 | Turnstone Biologics raises $41.4 Million Series B Financing | - |
| 02.11.2016 | Turnstone Biologics sees $41.4M Series B for oncolytic viral cancer R&D | Turnstone Biologics will use its new cash pot to both boost and expand its pipeline of oncolytic viral immunotherapies with help from new investors OrbiMed and F-Prime Capital Partners. The Canadian-based biotech has raised the cash less th... |
| 02.11.2016 | Turnstone Biologics Raises $41.4M in Series B Financing | Turnstone Biologics Inc., an Ottawa, Ontario, Canada-based developer of novel oncolytic viral immunotherapies, completed a $41.4m series B financing. The round was led by new investor OrbiMed with participation from new investor F-Prime Cap... |
| 02.11.2016 | Term Sheet — Wednesday, November 1 | Et cetera Money in the Bank: Yesterday’s Term Sheet included a last-minute deal announcement that deserves a little extra attention today: Battery Ventures, Andreessen Horowitz and Ribbit Capital invested $28 million in Cross River Bank. Pa... |
| 29.10.2015 | Today in funding ($51M): Turnstone Biologics, Invixium, Qvella, Elastic Path Software | This week, three Toronto-based companies raised impressive Series A rounds – two of them in healthtech. Here’s the latest on who raised how much, and from whom. Qvella raises $26 million series A Toronto-based Qvella, a leading molecular di... |
| 28.10.2015 | Daily funding roundup - October 28, 2015 | Alteryx bagged $85M; Paddle8 secured $34M; Personal Genome raised $21.4M A new startup called Localize wants to help companies outsource their international efforts. Specifically, Localize helps translate apps and websites into other langua... |
| 28.10.2015 | Turnstone Biologics Completes $11.3M Series A Financing Round | Turnstone Biologics Inc., a Toronto, Ontario, Canada-based developer of novel oncolytic viral immunotherapies, completed an $11.3m Series A financing round. The round was led by Versant Ventures with follow-on capital committed in excess of... |
Show more